GGrantIndex
← Search

Proteases Program

$27,932P30FY2007CANIH

Wayne State University, Detroit MI

Investigators

Linked publications, trials & patents

Trial NCT06501040Trial NCT04479267Trial NCT04397679Trial NCT04266522Trial NCT04159896Trial NCT03875053Trial NCT03683420Trial NCT03456804Trial NCT03454529Trial NCT03453489Trial NCT03406858Trial NCT03252600Trial NCT03147885Trial NCT02824029Trial NCT02819024Trial NCT02723604Trial NCT02620865Trial NCT02568449Trial NCT02521090Trial NCT02520115Trial NCT02472275Trial NCT02470559Trial NCT02359019Trial NCT02178436Trial NCT02178163Trial NCT02173093Trial NCT02145078Trial NCT02094872Trial NCT02058706Trial NCT02037256Trial NCT01987596Trial NCT01958372Trial NCT01698658Trial NCT01504711Trial NCT01281163Trial NCT01175980Trial NCT01147016Trial NCT01116232Trial NCT01071564Trial NCT01051570Trial NCT01022138Trial NCT00984919Trial NCT00972023Trial NCT00942422Trial NCT00938626Trial NCT00935090Trial NCT00918762Trial NCT00914147Trial NCT00906503Trial NCT00903214Trial NCT00899665Trial NCT00897910Trial NCT00897741Trial NCT00897494Trial NCT00897247Trial NCT00890617Trial NCT00888654Trial NCT00769288Trial NCT00768118Trial NCT00717535Trial NCT00691015Trial NCT00559897Trial NCT00541099Trial NCT00527124Trial NCT00521261Trial NCT00520767Trial NCT00514215Trial NCT00503841Trial NCT00499694Trial NCT00482846Trial NCT00459121Trial NCT00438204Trial NCT00423826Trial NCT00410904Trial NCT00376948Trial NCT00369109Trial NCT00305747Trial NCT00303901Trial NCT00301808Trial NCT00293384Trial NCT00288028Trial NCT00258466Trial NCT00258310Trial NCT00258284Trial NCT00258245Trial NCT00258232Trial NCT00248560Trial NCT00248482Trial NCT00244946Trial NCT00244933Trial NCT00243048Trial NCT00238329Trial NCT00227721Trial NCT00217581Trial NCT00121264Trial NCT00118157Trial NCT00078923Trial NCT00068653Trial NCT00066326Trial NCT00056004

Abstract

The Proteases and Cancer Program has primarily been a basic science program that has successfully worked to integrate translational and preclinical research into the program during the past three years. The research efforts of this program have concentrated on four major questions: (1) how the tumor microenvironment, including tumor/host interactions, alters proteolysis and the impact of this on anti-protease therapies; (2) what are the mechanisms (gene to protein) that regulate activation and inhibition of proteases and how can these be used to develop more efficacious inhibitors or alternative anti-protease strategies for use in vivo; (3) how proteases and their endogenous inhibitors function in normal developmental and non-cancerous pathological processes with the goal of identifying new therapeutic targets; and (4) what are the critical proteases and their functions in cell death and differentiation, also with the goal of identifying new targets. Proteases of the five endopeptidase classes are currently under study in the Program or through inter-programmatic collaborations in the Cancer Center. In terms of protease inhibitors, program members are performing structure-function analyses on endogenous protease inhibitors (e.g., tissue inhibitors of matrix metalloproteinases, plasminogen activator inhibitor-1, maspin, and cystatins), designing and testing known and novel synthetic inhibitors for matrix metalloproteinases, cysteine (calpain and cathepsin) and aspartic proteases and exploring other interactions that may modulate protease-associated functions (e.g., galectin-3, HB-EGF, annexin II heterotetramer, caveolae). Translational research efforts are directed toward: 1) development of novel protease inhibitors as potential therapeutic agents, 2) determining whether interactions that may modulate protease-associated functions might serve as novel targets for therapeutic intervention, and 3) developing novel methods and probes for in vitro and in vivo imaging of protease activity. There are four collaborative subprograms to explore these research areas with considerable crossover and collaboration among the subprograms and other Programs.

View original record on NIH RePORTER →